Novo Nordisk A/S (NYSE:NVO) Analyst Rating Consensus

Novo Nordisk A/S (NYSE:NVO) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 2 by 4 Brokerage Firm. 2 Wall Street Firms have rated the stock as a strong buys. 2 Brokerage Firms have advised hold.

Novo Nordisk A/S (NYSE:NVO) rose 1.05% or 0.54 points on Tuesday and made its way into the gainers of the day. After trading began at $52.47 the stock was seen hitting $52.5 as a peak level and $51.91 as the lowest level. The stock ended up at $52.15. The daily volume was measured at 1,653,932 shares. The 52-week high of the share price is $60.34 and the 52-week low is $46.17. The company has a market cap of $135,590 million.

Shares of Novo Nordisk A/S appreciated by 0.06% during the last five trading days but lost 3.28% on a 4-week basis. Novo Nordisk A/S has dropped 4.5% during the last 3-month period . Year-to-Date the stock performance stands at -8.62%.

Novo Nordisk A/S is a healthcare company. The Company is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. It has a range of diabetes product portfolio, including a portfolio of modern insulins as well as a human once-daily GLP-1 analog. It operates in two segments: diabetes care and biopharmaceuticals. The Companys diabetes care segment covers insulins, GLP-1, other protein-related products (such as glucagon, protein-related delivery systems and needles), oral anti-diabetic drugs and obesity. Its biopharmaceuticals segment covers the therapy areas of haemophilia care, growth hormone therapy and hormone replacement therapy. The primary production facilities owned by the Company are located at a number of sites in Denmark, and internationally in the United States, France, China and Brazil.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *